» Articles » PMID: 22198151

A Synthetic Double-stranded RNA, Poly I:C, Induces a Rapid Apoptosis of Human CD34(+) Cells

Overview
Journal Exp Hematol
Specialty Hematology
Date 2011 Dec 27
PMID 22198151
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Toll-like receptor 3 (TLR3), retinoic acid-inducible gene I, and melanoma differentiation-associated antigen 5 (RIG-I/MDA-5) helicases are known to sense double-stranded RNA (dsRNA) virus and initiate antiviral responses, such as production of type-I interferons (IFNs). Recognition of dsRNA by TLR3 or RIG-I/MDA-5 is cell-type-dependent and recent studies have shown a direct link between TLRs and hematopoiesis. We hypothesized that viral dsRNA recognized by either TLR3 or RIG-I/MDA-5, affects the growth of human hematopoietic stem/progenitor cells. Here we show that polyinosinic polycytidylic acid (poly I:C)-mediated very rapid apoptosis occurs within 1 hour in CD34(+) cells in a dose-dependent manner. Polyadenylic-polyuridylic acid, another synthetic dsRNA that signals only through TLR3, had no effect. Poly I:C-LMW/LyoVec, a complex between low molecular-weight poly I:C and the transfection reagent LyoVec, which signals only through RIG-I/MDA-5, induces apoptosis of CD34(+) cells. A strong and sustained upregulation of messenger RNA and protein levels of Noxa, a proapoptotic BH3-only protein that can be induced by RIG-I/MDA-5 pathway, is found in CD34(+) cells treated by poly I:C. Although poly I:C upregulates type-I IFNs in CD34(+) cells, neither exogenous IFN-α nor IFN-β induces rapid apoptosis in CD34(+) cells and neutralization or blocking of type-I IFN receptor does not rescue CD34(+) cells, whereas Z-VAD, a pan-caspase inhibitor, rescues the cells from apoptosis. These results suggest that RIG-I/MDA-5, but not TLR3, signaling triggers poly I:C-induced rapid apoptosis of human CD34(+) cells, which will provide an insight into the mechanisms of dsRNA virus-mediated hematopoietic disorders.

Citing Articles

Nucleic acid-induced inflammation on hematopoietic stem cells.

Vu G, Awad V, Norberto M, Bowman T, Trompouki E Exp Hematol. 2023; 131:104148.

PMID: 38151171 PMC: 11061806. DOI: 10.1016/j.exphem.2023.104148.


Correcting inborn errors of immunity: From viral mediated gene addition to gene editing.

Castiello M, Ferrari S, Villa A Semin Immunol. 2023; 66:101731.

PMID: 36863140 PMC: 10109147. DOI: 10.1016/j.smim.2023.101731.


Stem Cells as Target for Prostate cancer Therapy: Opportunities and Challenges.

Escudero-Lourdes C, Alvarado-Morales I, Tokar E Stem Cell Rev Rep. 2022; 18(8):2833-2851.

PMID: 35951166 PMC: 9716656. DOI: 10.1007/s12015-022-10437-6.


A Curative DNA Code for Hematopoietic Defects: Novel Cell Therapies for Monogenic Diseases of the Blood and Immune System.

Porteus M, Pavel-Dinu M, Pai S Hematol Oncol Clin North Am. 2022; 36(4):647-665.

PMID: 35773054 PMC: 9365196. DOI: 10.1016/j.hoc.2022.05.002.


Gene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation.

Ferrari S, Vavassori V, Canarutto D, Jacob A, Castiello M, Omer Javed A Front Genome Ed. 2021; 3:618378.

PMID: 34713250 PMC: 8525369. DOI: 10.3389/fgeed.2021.618378.